Clinical Management of Patients with Ebola Virus Disease in High-Resource Settings

  • G. Marshall Lyon
  • Aneesh K. Mehta
  • Bruce S. RibnerEmail author
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 411)


Like most viral illnesses in humans, supportive care of the patient is the mainstay of clinical care for patients with Ebola virus disease (EVD). The goal is to maintain and sustain the patient until a specific immune response develops and clears the viral infection. Clearly, antiviral therapy may eventually help speed recovery, but supportive care will likely always be the centerpiece of care of the patient with EVD. While terrible in terms of human suffering and loss, the EVD outbreak of 2014–2016 provided an unheralded opportunity to advance our understanding in the care of patients (WHO 2016). Regardless of the care setting, resource-rich or resource-constrained, it is beneficial to have an established team of care providers. This team should consist of nurses and physicians who are familiar with clinical care of patients with EVD and have demonstrated competency using necessary personal protective equipment (PPE). Consideration should be given to having several physician specialties on the team, including critical care, infectious diseases, and anesthesiology. Additional individuals in other medical specialties should be identified in case needed during the course of caring for a patient. The National Ebola Training and Education Center (NETEC) has detailed guidance on preparations for developing a high-containment unit and care team (NETEC 2016).


  1. Agnandji ST, Huttner A, Zinser ME, Njuguna P, Dahlke C, Fernandes JF, Yerly S, Dayer J-A, Kraehling V, Kasonta R, Adegnika AA, Altfeld M, Auderset F, Bache EB, Biedenkopf N, Borregaard S, Brosnahan JS, Burrow R, Combescure C, Desmeules J, Eickmann M, Fehling SK, Finckh A, Goncalves AR, Grobusch MP, Hooper J, Jambrecina A, Kabwende AL, Kaya G, Kimani D, Lell B, Lemaître B, Lohse AW, Massinga-Loembe M, Matthey A, Mordmüller B, Nolting A, Ogwang C, Ramharter M, Schmidt-Chanasit J, Schmiedel S, Silvera P, Stahl FR, Staines HM, Strecker T, Stubbe HC, Tsofa B, Zaki S, Fast P, Moorthy V, Kaiser L, Krishna S, Becker S, Kieny M-P, Bejon P, Kremsner PG, Addo MM, Siegrist C-A (2016) Phase 1 trials of rVSV Ebola vaccine in Africa and Europe. N Engl J Med 374(17):1647–1660. doi: 10.1056/NEJMoa1502924 CrossRefPubMedGoogle Scholar
  2. Bah EI, Lamah MC, Fletcher T, Jacob ST, Brett-Major DM, Sall AA, Shindo N, Fischer WA 2nd, Lamontagne F, Saliou SM, Bausch DG, Moumie B, Jagatic T, Sprecher A, Lawler JV, Mayet T, Jacquerioz FA, Mendez Baggi MF, Vallenas C, Clement C, Mardel S, Faye O, Faye O, Soropogui B, Magassouba N, Koivogui L, Pinto R, Fowler RA (2015) Clinical presentation of patients with Ebola virus disease in Conakry, Guinea. N Engl J Med 372(1):40–47. doi: 10.1056/NEJMoa1411249 CrossRefPubMedGoogle Scholar
  3. Bausch DG, Towner JS, Dowell SF, Kaducu F, Lukwiya M, Sanchez A, Nichol ST, Ksiazek TG, Rollin PE (2007) Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J Infect Dis 196(Suppl 2):S142–S147. doi: 10.1086/520545 CrossRefPubMedGoogle Scholar
  4. CDC (2016a) Guidance on Personal Protective Equipment (PPE) to be used by healthcare workers during management of patients with confirmed Ebola or Persons under Investigation (PUIs) for Ebola who are clinically unstable or have bleeding, vomiting, or diarrhea in U.S. Hospitals, Including procedures for Donning and Doffing PPE. Accessed 1 June 2016
  5. CDC (2016b) Interim guidance for environmental infection control in hospitals for Ebola Virus. Accessed 1 June 2016
  6. Chertow DS, Kleine C, Edwards JK, Scaini R, Giuliani R, Sprecher A (2014) Ebola virus disease in West Africa–clinical manifestations and management. N Engl J Med 371(22):2054–2057. doi: 10.1056/NEJMp1413084 CrossRefPubMedGoogle Scholar
  7. Chertow DS, Uyeki TM, DuPont HL (2015) Loperamide therapy for voluminous diarrhea in Ebola virus disease. J Infect Dis 211(7):1036–1037. doi: 10.1093/infdis/jiv001 CrossRefPubMedPubMedCentralGoogle Scholar
  8. Connor MJ Jr, Kraft C, Mehta AK, Varkey JB, Lyon GM, Crozier I, Stroher U, Ribner BS, Franch HA (2015) Successful delivery of RRT in Ebola virus disease. J Am Soc Nephrology: JASN 26(1):31–37. doi: 10.1681/ASN.2014111057 CrossRefGoogle Scholar
  9. Dallatomasina S, Crestani R, Sylvester Squire J, Declerk H, Caleo GM, Wolz A, Stinson K, Patten G, Brechard R, Gbabai OB, Spreicher A, Van Herp M, Zachariah R (2015) Ebola outbreak in rural West Africa: epidemiology, clinical features and outcomes. Trop Med Int Health 20(4):448–454. doi: 10.1111/tmi.12454 CrossRefPubMedPubMedCentralGoogle Scholar
  10. Del Rio C, Mehta AK, Lyon GM 3rd, Guarner J (2014) Ebola hemorrhagic fever in 2014: the tale of an evolving epidemic. Ann Intern Med 161(10):746–748. doi: 10.7326/M14-1880 CrossRefPubMedGoogle Scholar
  11. Dowell SF, Mukunu R, Ksiazek TG, Khan AS, Rollin PE, Peters CJ (1999) Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis 179 Suppl 1:S87–91. doi: 10.1086/514284
  12. Dunning J, Sahr F, Rojek A, Gannon F, Carson G, Idriss B, Massaquoi T, Gandi R, Joseph S, Osman HK, Brooks TJG, Simpson AJH, Goodfellow I, Thorne L, Arias A, Merson L, Castle L, Howell-Jones R, Pardinaz-Solis R, Hope-Gill B, Ferri M, Grove J, Kowalski M, Stepniewska K, Lang T, Whitehead J, Olliaro P, Samai M, Horby PW, for the R-TKMtt (2016) Experimental treatment of Ebola Virus disease with TKM-130803: a single-arm phase 2 clinical trial. PLoS Med 13(4):e1001997. doi: 10.1371/journal.pmed.1001997
  13. Emond RT, Evans B, Bowen ET, Lloyd G (1977) A case of Ebola virus infection. BMJ 2(6086):541–544. doi: 10.1136/bmj.2.6086.541 CrossRefPubMedPubMedCentralGoogle Scholar
  14. EPA (2016) List L: disinfectants for use against the Ebola virus. Accessed 1 June 2016
  15. Ewer K, Rampling T, Venkatraman N, Bowyer G, Wright D, Lambe T, Imoukhuede EB, Payne R, Fehling SK, Strecker T, Biedenkopf N, Krähling V, Tully CM, Edwards NJ, Bentley EM, Samuel D, Labbé G, Jin J, Gibani M, Minhinnick A, Wilkie M, Poulton I, Lella N, Roberts R, Hartnell F, Bliss C, Sierra-Davidson K, Powlson J, Berrie E, Tedder R, Roman F, De Ryck I, Nicosia A, Sullivan NJ, Stanley DA, Mbaya OT, Ledgerwood JE, Schwartz RM, Siani L, Colloca S, Folgori A, Di Marco S, Cortese R, Wright E, Becker S, Graham BS, Koup RA, Levine MM, Volkmann A, Chaplin P, Pollard AJ, Draper SJ, Ballou WR, Lawrie A, Gilbert SC, Hill AVS (2016) A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA. N Engl J Med 374(17):1635–1646. doi: 10.1056/NEJMoa1411627 CrossRefPubMedGoogle Scholar
  16. Fischer R, Judson S, Miazgowicz K, Bushmaker T, Prescott J, Munster VJ (2015) Ebola virus stability on surfaces and in fluids in simulated outbreak environments. Emerg Infect Dis 21(7):1243–1246. doi: 10.3201/eid2107.150253 CrossRefPubMedPubMedCentralGoogle Scholar
  17. Florescu DF, Kalil AC, Hewlett AL, Schuh AJ, Stroher U, Uyeki TM, Smith PW (2015) Administration of brincidofovir and convalescent plasma in a patient with Ebola virus disease. Clin Infect Dis 61(6):969–973. doi: 10.1093/cid/civ395 CrossRefPubMedGoogle Scholar
  18. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL (2013) Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 100(2):446–454. doi: 10.1016/j.antiviral.2013.09.015 CrossRefPubMedGoogle Scholar
  19. Geisbert TW, Lee ACH, Robbins M, Geisbert JB, Honko AN, Sood V, Johnson JC, de Jong S, Tavakoli I, Judge A, Hensley LE, MacLachlan I (2010) Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. The Lancet 375(9729):1896–1905. doi: 10.1016/S0140-6736(10)60357-1 CrossRefGoogle Scholar
  20. Geisbert TW (2015) Marburg and Ebola Hemorrhagic Fevers (Marburg and Ebola Viral Diseases) (Filoviruses)-In: Bennett JE, Dolin RMD, Blaser MJ (eds) Mandell, Douglas, and Bennett’s Principles and practice of infectious diseases, Updated Edition, 166, 1995–1999. ivGoogle Scholar
  21. Guidet B, Soni N, Rocca GD, Kozek S, Vallet B, Annane D, James M (2010) A balanced view of balanced solutions. Crit Care 14(5):1–12. doi: 10.1186/cc9230 CrossRefGoogle Scholar
  22. Heald AE, Iversen PL, Saoud JB, Sazani P, Charleston JS, Axtelle T, Wong M, Smith WB, Vutikullird A, Kaye E (2014) Safety and pharmacokinetic profiles of phosphorodiamidate morpholino oligomers with activity against ebola virus and marburg virus: results of two single-ascending-dose studies. Antimicrob Agents Chemother 58(11):6639–6647. doi: 10.1128/aac.03442-14 CrossRefPubMedPubMedCentralGoogle Scholar
  23. Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, Camacho A, Carroll MW, Doumbia M, Draguez B, Duraffour S, Enwere G, Grais R, Gunther S, Hossmann S, Kondé MK, Kone S, Kuisma E, Levine MM, Mandal S, Norheim G, Riveros X, Soumah A, Trelle S, Vicari AS, Watson CH, Kéïta S, Kieny MP, Røttingen J-A (2015) Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386 (9996):857–866. doi: 10.1016/S0140-6736(15)61117-5
  24. Huttner A, Dayer J A, Yerly S, Combescure C, Auderset F, Desmeules J, Eickmann M, Finckh A, Goncalves AR, Hooper JW, Kaya G, Krähling V, Kwilas S, Lemaître B, Matthey A, Silvera P, Becker S, Fast PE, Moorthy V, Kieny MP, Kaiser L, Siegrist C-A (2015) The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis 15 (10):1156–1166. doi: 10.1016/S1473-3099(15)00154-1
  25. Iwen PC, Smith PW, Hewlett AL, Kratochvil CJ, Lisco SJ, Sullivan JN, Gibbs SG, Lowe JJ, Fey PD, Herrera VL, Sambol AR, Wisecarver JL, Hinrichs SH (2015) Safety considerations in the laboratory testing of specimens suspected or known to contain Ebola virus. Am J Clin Pathol 143(1):4–5. doi: 10.1309/AJCP26MIFUIETBPL CrossRefPubMedGoogle Scholar
  26. Jacobs M, Rodger A, Bell DJ, Bhagani S, Cropley I, Filipe A, Gifford RJ, Hopkins S, Hughes J, Jabeen F, Johannessen I, Karageorgopoulos D, Lackenby A, Lester R, Liu RS, MacConnachie A, Mahungu T, Martin D, Marshall N, Mepham S, Orton R, Palmarini M, Patel M, Perry C, Peters SE, Porter D, Ritchie D, Ritchie ND, Seaton RA, Sreenu VB, Templeton K, Warren S, Wilkie GS, Zambon M, Gopal R, Thomson EC (2016) Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet 388(10043):498–503. doi: 10.1016/S0140-6736(16)30386-5 CrossRefPubMedPubMedCentralGoogle Scholar
  27. Khan AS, Tshioko FK, Heymann DL, Le Guenno B, Nabeth P, Kerstiens B, Fleerackers Y, Kilmarx PH, Rodier GR, Nkuku O, Rollin PE, Sanchez A, Zaki SR, Swanepoel R, Tomori O, Nichol ST, Peters CJ, Muyembe-Tamfum JJ, Ksiazek TG (1999) The reemergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis 179 Suppl 1:S76–86. doi: 10.1086/514306
  28. Kibadi K, Mupapa K, Kuvula K, Massamba M, Ndaberey D, Muyembe-Tamfum JJ, Bwaka MA, De Roo A, Colebunders R (1999) Late ophthalmologic manifestations in survivors of the 1995 Ebola virus epidemic in Kikwit, democratic Republic of the Congo. J Infect Dis 179(Suppl 1):S13–S14. doi: 10.1086/514288 CrossRefPubMedGoogle Scholar
  29. Kraft CS, Hewlett AL, Koepsell S, Winkler AM, Kratochvil CJ, Larson L, Varkey JB, Mehta AK, Lyon GM, 3rd, Friedman-Moraco RJ, Marconi VC, Hill CE, Sullivan JN, Johnson DW, Lisco SJ, Mulligan MJ, Uyeki TM, McElroy AK, Sealy T, Campbell S, Spiropoulou C, Stroher U, Crozier I, Sacra R, Connor MJ, Jr., Sueblinvong V, Franch HA, Smith PW, Ribner BS, Nebraska Biocontainment U, the Emory Serious Communicable Diseases U (2015) The Use of TKM-100802 and convalescent plasma in 2 patients with Ebola Virus disease in the United States. Clin Infect Dis 61 (4):496–502. doi: 10.1093/cid/civ334
  30. Liddell AM, Davey RT Jr, Mehta AK, Varkey JB, Kraft CS, Tseggay GK, Badidi O, Faust AC, Brown KV, Suffredini AF, Barrett K, Wolcott MJ, Marconi VC, Lyon GM 3rd, Weinstein GL, Weinmeister K, Sutton S, Hazbun M, Albarino CG, Reed Z, Cannon D, Stroher U, Feldman M, Ribner BS, Lane HC, Fauci AS, Uyeki TM (2015) Characteristics and clinical management of a cluster of 3 patients with Ebola Virus disease, including the first domestically acquired cases in the United States. Ann Intern Med 163(2):81–90. doi: 10.7326/M15-0530 CrossRefPubMedPubMedCentralGoogle Scholar
  31. Lyon GM, Mehta AK, Varkey JB, Brantly K, Plyler L, McElroy AK, Kraft CS, Towner JS, Spiropoulou C, Stroher U, Uyeki TM, Ribner BS (2014) Emory Serious Communicable Diseases U (2014) Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med 371 (25):2402–2409. doi: 10.1056/NEJMoa1409838
  32. Madelain V, Nguyen THT, Olivo A, de Lamballerie X, Guedj J, Taburet A-M, Mentré F (2016) Ebola virus infection: review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials. Clin Pharmacokinet 55(8):907–923. doi: 10.1007/s40262-015-0364-1 CrossRefPubMedGoogle Scholar
  33. Martines RB, Ng DL, Greer PW, Rollin PE, Zaki SR (2015) Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses. J Pathol 235(2):153–174. doi: 10.1002/path.4456 CrossRefPubMedGoogle Scholar
  34. Martins KA, Jahrling PB, Bavari S, Kuhn JH (2016) Ebola virus disease candidate vaccines under evaluation in clinical trials. Expert Rev Vaccines 15(9):1101–1112. doi: 10.1080/14760584.2016.1187566 CrossRefPubMedPubMedCentralGoogle Scholar
  35. Mate SE, Kugelman JR, Nyenswah TG, Ladner JT, Wiley MR, Cordier-Lassalle T, Christie A, Schroth GP, Gross SM, Davies-Wayne GJ, Shinde SA, Murugan R, Sieh SB, Badio M, Fakoli L, Taweh F, de Wit E, van Doremalen N, Munster VJ, Pettitt J, Prieto K, Humrighouse BW, Stroher U, DiClaro JW, Hensley LE, Schoepp RJ, Safronetz D, Fair J, Kuhn JH, Blackley DJ, Laney AS, Williams DE, Lo T, Gasasira A, Nichol ST, Formenty P, Kateh FN, De Cock KM, Bolay F, Sanchez-Lockhart M, Palacios G (2015) Molecular evidence of sexual transmission of Ebola Virus. N Engl J Med 373(25):2448–2454. doi: 10.1056/NEJMoa1509773 CrossRefPubMedPubMedCentralGoogle Scholar
  36. Mendoza EJ, Qiu X, Kobinger GP (2016) Progression of Ebola therapeutics during the 2014–2015 outbreak. Trends Mol Med 22(2):164–173. doi: 10.1016/j.molmed.2015.12.005 CrossRefPubMedGoogle Scholar
  37. Milligan ID, Gibani MM, Sewell R et al (2016) Safety and immunogenicity of novel adenovirus type 26––and modified vaccinia ankara––vectored Ebola vaccines: a randomized clinical trial. JAMA 315(15):1610–1623. doi: 10.1001/jama.2016.4218 CrossRefPubMedGoogle Scholar
  38. Mupapa K, Massamba M, Kibadi K, Kuvula K, Bwaka A, Kipasa M, Colebunders R, Muyembe-Tamfum JJ (1999) Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis 179 Suppl 1:S18–23. doi: 10.1086/514298
  39. Ndambi R, Akamituna P, Bonnet MJ, Tukadila AM, Muyembe-Tamfum JJ, Colebunders R (1999) Epidemiologic and clinical aspects of the Ebola virus epidemic in Mosango, Democratic Republic of the Congo, 1995. J Infect Dis 179(Suppl 1):S8–10. doi: 10.1086/514297 CrossRefPubMedGoogle Scholar
  40. NETEC (2016) National Ebola Training & Education Center. Accessed 30 Aug 2016
  41. NewLink Genetics Corporation (2016) NewLink genetics announces merck receives breakthrough therapy designation from FDA and PRIME status from EMA for Investigational Ebola Zaire Vaccine (V920). Accessed 15 Sept 2016
  42. Ohimain EI (2016) Recent advances in the development of vaccines for Ebola virus disease. Virus Res 211:174–185. doi: 10.1016/j.virusres.2015.10.021 CrossRefPubMedGoogle Scholar
  43. Peters CJ, Jahrling PB, Khan AS (1996) Patients infected with high-hazard viruses: scientific basis for infection control. Arch Virol Suppl 11:141–168PubMedGoogle Scholar
  44. Qin E, Bi J, Zhao M, Wang Y, Guo T, Yan T, Li Z, Sun J, Zhang J, Chen S, Wu Y, Li J, Zhong Y (2015) Clinical features of patients with Ebola virus disease in sierra leone. Clin Infect Dis 61(4):491–495. doi: 10.1093/cid/civ319 CrossRefPubMedGoogle Scholar
  45. Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, Fausther-Bovendo H, Wei H, Aviles J, Hiatt E, Johnson A, Morton J, Swope K, Bohorov O, Bohorova N, Goodman C, Kim D, Pauly MH, Velasco J, Pettitt J, Olinger GG, Whaley K, Xu B, Strong JE, Zeitlin L, Kobinger GP (2014) Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514(7520):47–53. doi: 10.1038/nature13777 CrossRefPubMedPubMedCentralGoogle Scholar
  46. Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Muñoz P, Moon JE, Ruck RC, Bennett JW, Twomey PS, Gutiérrez RL, Remich SA, Hack HR, Wisniewski ML, Josleyn MD, Kwilas SA, Van Deusen N, Mbaya OT, Zhou Y, Stanley DA, Bliss RL, Cebrik D, Smith KS, Shi M, Ledgerwood JE, Graham BS, Sullivan NJ, Jagodzinski LL, Peel SA, Alimonti JB, Hooper JW, Silvera PM, Martin BK, Monath TP, Ramsey WJ, Link CJ, Lane HC, Michael NL, Davey RTJ, Thomas SJ (2017) A recombinant vesicular stomatitis virus Ebola Vaccine––Preliminary report. N Engl J Med 0 (0):null. doi: 10.1056/NEJMoa1414216
  47. Respiratory vaccine shows promise (2014). Can Nurse 110 (9):8Google Scholar
  48. Roberts A, Buonocore L, Price R, Forman J, Rose JK (1999) Attenuated vesicular stomatitis viruses as vaccine vectors. J Virol 73(5):3723–3732PubMedPubMedCentralGoogle Scholar
  49. Roddy P, Howard N, Van Kerkhove MD, Lutwama J, Wamala J, Yoti Z, Colebunders R, Palma PP, Sterk E, Jeffs B, Van Herp M, Borchert M (2012) Clinical manifestations and case management of Ebola haemorrhagic fever caused by a newly identified virus strain, bundibugyo, uganda, 2007–2008. PLoS ONE 7(12):e52986. doi: 10.1371/journal.pone.0052986 CrossRefPubMedPubMedCentralGoogle Scholar
  50. Schieffelin JS, Shaffer JG, Goba A, Gbakie M, Gire SK, Colubri A, Sealfon RS, Kanneh L, Moigboi A, Momoh M, Fullah M, Moses LM, Brown BL, Andersen KG, Winnicki S, Schaffner SF, Park DJ, Yozwiak NL, Jiang PP, Kargbo D, Jalloh S, Fonnie M, Sinnah V, French I, Kovoma A, Kamara FK, Tucker V, Konuwa E, Sellu J, Mustapha I, Foday M, Yillah M, Kanneh F, Saffa S, Massally JL, Boisen ML, Branco LM, Vandi MA, Grant DS, Happi C, Gevao SM, Fletcher TE, Fowler RA, Bausch DG, Sabeti PC, Khan SH, Garry RF, Program KGHLF, Viral Hemorrhagic Fever C, Team WHOCR (2014) Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med 371(22):2092–2100. doi: 10.1056/NEJMoa1411680 CrossRefPubMedPubMedCentralGoogle Scholar
  51. Scott JT, Sesay FR, Massaquoi TA, Idriss BR, Sahr F, Semple MG (2016) Post-ebola syndrome Sierra Leone. Emerg Infect Dis 22(4):641–646. doi: 10.3201/eid2204.151302 CrossRefPubMedPubMedCentralGoogle Scholar
  52. Sissoko D, Laouenan C, Folkesson E, M’Lebing A-B, Beavogui A-H, Baize S, Camara A-M, Maes P, Shepherd S, Danel C, Carazo S, Conde MN, Gala J-L, Colin G, Savini H, Bore JA, Le Marcis F, Koundouno FR, Petitjean F, Lamah M-C, Diederich S, Tounkara A, Poelart G, Berbain E, Dindart J-M, Duraffour S, Lefevre A, Leno T, Peyrouset O, Irenge L, Bangoura NF, Palich R, Hinzmann J, Kraus A, Barry TS, Berette S, Bongono A, Camara MS, Chanfreau Munoz V, Doumbouya L, Souley H, Kighoma PM, Koundouno FR, Réné L, Loua CM, Massala V, Moumouni K, Provost C, Samake N, Sekou C, Soumah A, Arnould I, Komano MS, Gustin L, Berutto C, Camara D, Camara FS, Colpaert J, Delamou L, Jansson L, Kourouma E, Loua M, Malme K, Manfrin E, Maomou A, Milinouno A, Ombelet S, Sidiboun AY, Verreckt I, Yombouno P, Bocquin A, Carbonnelle C, Carmoi T, Frange P, Mely S, Nguyen V-K, Pannetier D, Taburet A-M, Treluyer J-M, Kolie J, Moh R, Gonzalez MC, Kuisma E, Liedigk B, Ngabo D, Rudolf M, Thom R, Kerber R, Gabriel M, Di Caro A, Wölfel R, Badir J, Bentahir M, Deccache Y, Dumont C, Durant J-F, El Bakkouri K, Gasasira Uwamahoro M, Smits B, Toufik N, Van Cauwenberghe S, Ezzedine K, Dortenzio E, Pizarro L, Etienne A, Guedj J, Fizet A, Barte de Sainte Fare E, Murgue B, Tran-Minh T, Rapp C, Piguet P, Poncin M, Draguez B, Allaford Duverger T, Barbe S, Baret G, Defourny I, Carroll M, Raoul H, Augier A, Eholie SP, Yazdanpanah Y, Levy-Marchal C, Antierrens A, Van Herp M, Günther S, de Lamballerie X, Keïta S, Mentre F, Anglaret X, Malvy D, Group JS (2016) Experimental treatment with favipiravir for ebola virus disease (the jiki trial): a historically controlled, single-arm proof-of-concept trial in guinea. PLoS Med 13 (3):e1001967. doi: 10.1371/journal.pmed.1001967
  53. Sueblinvong V, Johnson DW, Weinstein GL, Connor MJ Jr, Crozier I, Liddell AM, Franch HA, Wall BR, Kalil AC, Feldman M, Lisco SJ, Sevransky JE (2015) Critical care for multiple organ failure secondary to Ebola virus disease in the united states. Crit Care Med 43(10):2066–2075. doi: 10.1097/CCM.0000000000001197 CrossRefPubMedPubMedCentralGoogle Scholar
  54. Tapia MD, Sow SO, Lyke KE, Haidara FC, Diallo F, Doumbia M, Traore A, Coulibaly F, Kodio M, Onwuchekwa U, Sztein MB, Wahid R, Campbell JD, Kieny M-P, Moorthy V, Imoukhuede EB, Rampling T, Roman F, De Ryck I, Bellamy AR, Dally L, Mbaya OT, Ploquin A, Zhou Y, Stanley DA, Bailer R, Koup RA, Roederer M, Ledgerwood J, Hill AVS, Ballou WR, Sullivan N, Graham B, Levine MM (2016) Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 16 (1):31-42. doi: 10.1016/S1473-3099(15)00362-X
  55. Taylor R, Kotian P, Warren T, Panchal R, Bavari S, Julander J, Dobo S, Rose A, El-Kattan Y, Taubenheim B, Babu Y, Sheridan WP (2016) BCX4430––A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease. J Infect Public Health 9(3):220–226. doi: 10.1016/j.jiph.2016.04.002 CrossRefPubMedPubMedCentralGoogle Scholar
  56. Thi EP, Mire CE, Lee ACH, Geisbert JB, Zhou JZ, Agans KN, Snead NM, Deer DJ, Barnard TR, Fenton KA, MacLachlan I, Geisbert TW (2015) Lipid nanoparticle siRNA treatment of ebola-virus-makona-infected nonhuman primates. Nature 521(7552):362–365. doi: 10.1038/nature14442 CrossRefPubMedPubMedCentralGoogle Scholar
  57. Towner JS, Rollin PE, Bausch DG, Sanchez A, Crary SM, Vincent M, Lee WF, Spiropoulou CF, Ksiazek TG, Lukwiya M, Kaducu F, Downing R, Nichol ST (2004) Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol 78(8):4330–4341CrossRefPubMedPubMedCentralGoogle Scholar
  58. Uyeki TM, Erickson BR, Brown S, McElroy AK, Cannon D, Gibbons A, Sealy T, Kainulainen MH, Schuh AJ, Kraft CS, Mehta AK, Lyon GM 3rd, Varkey JB, Ribner BS, Ellison RT 3rd, Carmody E, Nau GJ, Spiropoulou C, Nichol ST, Stroher U (2016) Ebola virus persistence in Semen of male survivors. Clin Infect Dis 62(12):1552–1555. doi: 10.1093/cid/ciw202 CrossRefPubMedGoogle Scholar
  59. Uyeki TM, Mehta AK, Davey RT, Jr., Liddell AM, Wolf T, Vetter P, Schmiedel S, Grunewald T, Jacobs M, Arribas JR, Evans L, Hewlett AL, Brantsaeter AB, Ippolito G, Rapp C, Hoepelman AI, Gutman J, Working Group of the USECNoCMoEVDPitUS, Europe (2016b) Clinical management of Ebola virus disease in the United States and Europe. N Engl J Med 374 (7):636–646. doi: 10.1056/NEJMoa1504874
  60. Varkey JB (2016)Google Scholar
  61. Varkey JB, Shantha JG, Crozier I, Kraft CS, Lyon GM, Mehta AK, Kumar G, Smith JR, Kainulainen MH, Whitmer S, Stroher U, Uyeki TM, Ribner BS, Yeh S (2015) Persistence of Ebola Virus in Ocular fluid during convalescence. N Engl J Med 372(25):2423–2427. doi: 10.1056/NEJMoa1500306 CrossRefPubMedPubMedCentralGoogle Scholar
  62. Warren TK, Whitehouse CA, Wells J, Welch L, Heald AE, Charleston JS, Sazani P, Reid SP, Iversen PL, Bavari S (2015) A single phosphorodiamidate morpholino oligomer targeting VP24 protects Rhesus Monkeys against Lethal Ebola Virus Infection. mBio 6 (1):e02344–02314. doi: 10.1128/mBio.02344-14
  63. WHO (2016) Ebola situation report. Accessed 30 Aug 2016
  64. Winkler AM, Koepsell SA (2015) The use of convalescent plasma to treat emerging infectious diseases: focus on Ebola virus disease. Curr Opin Hematol 22(6):521–526. doi: 10.1097/moh.0000000000000191 CrossRefPubMedGoogle Scholar
  65. Wolf T, Kann G, Becker S, Stephan C, Brodt HR, de Leuw P, Grunewald T, Vogl T, Kempf VA, Keppler OT, Zacharowski K (2015) Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care. Lancet 385(9976):1428–1435. doi: 10.1016/S0140-6736(14)62384-9 CrossRefPubMedGoogle Scholar
  66. World Health Organization (WHO) (2014) Use of convalescent whole blood or plasma collected from patients recovered from Ebola Virus disease for transfusion, as an empirical treatment during outbreaks.,-as-an-empirical-treatment-during-outbreaks-eng.pdf. Accessed 10 July 2016
  67. Zeitlin L, Whaley KJ, Olinger GG, Jacobs M, Gopal R, Qiu X, Kobinger GP (2016) Antibody therapeutics for Ebola virus disease. Current Opin Virol 17:45–49. doi: 10.1016/j.coviro.2016.01.006 CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • G. Marshall Lyon
    • 1
  • Aneesh K. Mehta
    • 2
  • Bruce S. Ribner
    • 3
    Email author
  1. 1.Division of Infectious DiseasesEmory University School of MedicineAtlantaUSA
  2. 2.Department of Medicine, Division of Infectious DiseasesEmory University School of MedicineAtlantaUSA
  3. 3.Department of Medicine, Division of Infectious DiseasesEmory University School of Medicine, Emory University HospitalAtlantaUSA

Personalised recommendations